Keywords: Novartis, EU, Tasigna, Myeloid leukemia, Bexsero, Meningococcal B vaccine

Novartis gains EU approval for Tasigna in new Ph+ CML patients; files Bexsero MAA

Article | 24 December 2010

Print This

Novartis (NOVN: VX) said yesterday that it has received approval from the European Commission for Tasigna (nilotinib) as a treatment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in